Identification, characterization and synthesis of impurities of zafirlukast

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 4, 2009, Pages 895-900

  Goverdhan, Gilla ^a   Reddy, Anumula Raghupathi ^a   Srinivas, Kurella ^a   Himabindu, Vurimidi ^b   Reddy, Ghanta Mahesh ^c  

^a DR REDDY'S LABORATORIES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^c GVK BIOSCIENCES PVT LTD   (India)

Author keywords

Impurities; Isolation; Preparative HPLC; Regioisomers; Zafirlukast

Indexed keywords

3 METHOXY 4 (5 METHOXYCARBONYLAMINO 1 METHYL 1H INDOL 3 YLMETHYL)BENZOIC ACID; 4 (5 CYCLOPENTYLOXYCARBONYLAMINO 1 METHYL 1H INDOL 3 YL METHYL) 3 METHOXYBENZOIC ACID METHYL ESTER; [3 [2 METHOXY 4 (TOLUENE 2 SULFONYLAMINOCARBONYL)BENZYL] 1 METHYL 1H INDOL 5 YL]CARBAMIC ACID METHYL ESTER; [3 [2 METHOXY 4 (TOLUENE 3 SULFONYLAMINOCARBONYL)BENZYL] 1 METHYL 1H INDOL 5 YL]ACETIC ACID CYCLOPENTYL ESTER; [3 [2 METHOXY 4 (TOLUENE 4 SULFONYLAMINOCARBONYL)BENZYL] 1 METHYL 1H INDOL 5 YL]ACETIC ACID CYCLOPENTYL ESTER; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ARTICLE; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; INFRARED RADIATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTI-ASTHMATIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; ISOMERISM; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TOSYL COMPOUNDS;

EID: 62949241957     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.01.023     Document Type: Article

References (7)

1. Phipatanakul W., Eggleston P.A., Conover-Walker M.K., Kesavanathan J., Sweitzer D., and Wood R.A. J. Allergy Clin. Immunol. 105 (2000) 704-710
2. P.R. Bernstein, F.J. Brown, V.G. Matassa, Y.K. Yee, U.S. Patent, 4,859,692 (1989).
3. Ficarra R., Ficarra P., Tommasini S., Melardi S., Calabro M.L., Furlanetto S., and Semreen M. J. Pharm. Biomed. Anal. 23 (2000) 169-174
4. Radhakrishna T., Satyanarayana J., and Satyanarayana A. J. Pharm. Biomed. Anal. 30 (2002) 695-703
5. Suslu I., Demircan S., Alti{dotless}noz S., and Ki{dotless}r S. J. Pharm. Biomed. Anal. 44 (2007) 16-22
6. Goverdhan G., Reddy A.R., Sampath A., Srinivas K., Himabindu V., and Reddy G.M. Org. Process Res. Dev. 13 (2009) 67-72
7. ICH Guideline Q3A (R), Impurities in New Drug Substances, February 7, 2002.